tbuckley/cabot-search huggingface dataset:
Abstract P085: Effects of Psychological Factors on the Risk of Cardiovascular Diseases in Adolescents
Authors: Zhen Zhang, Ren Rong Gong, Yong Yan Song, Yuan Hao Li, Minshan Hu, Rong Hui Li, Mei Fan, Zhe Jiang, Xingchun Zhu, Hui Liu, Ding Zhi Fang, Mao Sheng Ran
Journal: Circulation (2012)

The association of psychological factors with the risk of cardiovascular diseases (CVD) has been reported before. However, few studies have evaluated whether psychological factors are associated with increased risk of CVD in adolescents with longitudinal design. Our hypothesis is that post-traumatic stress disorder (PTSD) and depression may increase the risk of CVD by changing its risk factors in adolescents. A total of 746 students at a high school 10 km away from the epicenter of Wenchuan earthquake were enrolled 6 months after the earthquake, and was followed up at 18 months. A total of 737 (98.8%) students completed the study 6 months after the earthquake. In the 18-month follow-up, 478 (64.1%) students completed the study. PTSD was assessed using PTSD Checklist-Civilian Version. Beck Depression Inventory (BDI) was used to assess depression. Fasting blood samples were collected. Serum variables of lipid and glucose metabolism were analyzed. The prevalences of PTSD symptoms were 10.6% and 1.9% at 6- and 18-month follow-up respectively. At 6- and 18-month follow-up, 40.7% and 30.3% of the students were found to have depression. The subjects with PTSD had significantly higher BMI ( p &lt;0.05), WHR ( p &lt;0.05) and triglyceride (TG) ( p &lt;0.05) than subjects with no PTSD 6 months after the earthquake. The boy subjects with PTSD had significantly higher BMI ( p &lt;0.05) than boy subjects with no PTSD. The girl subjects with PTSD had significantly higher BMI ( p &lt;0.05) and WHR ( p &lt;0.05) than girl subjects with no PTSD. In the 18-month follow-up study, the boy subjects with PTSD had significantly lower WHR ( p &lt;0.05) than boy subjects with no PTSD. Six months after the earthquake, subjects with depression had significantly higher BMI ( p &lt;0.05) and WHR ( p &lt;0.05) than subjects with no depression. The boy subjects with depression had significantly higher WHR ( p &lt;0.05) than boy subjects with no depression. The girl subjects with depression had significantly lower total cholesterol (TC) ( p &lt;0.05) than girl subjects with no depression. In the 18-month follow-up study, subjects with depression had significantly lower HDL-cholesterol (HDL-C) ( p &lt;0.05) than subjects with no depression. The boy subjects with depression had significantly higher systolic pressure ( p &lt;0.05), higher LDL-cholesterol (LDL-C) ( p &lt;0.05) but lower HDL-C ( p &lt;0.05) than boy subjects with no depression. The girl subjects with depression had significantly lower systolic pressure ( p &lt;0.05) and HDL-C ( p &lt;0.05) than girl subjects with no depression. These findings provide preliminary evidence linking of PTSD and depression symptoms with risk factors for CVD in adolescents.
Cell Kinetics and Chemotherapy in Neuroblastoma12
Authors: F. A. Hayes, A. M. Mauer
Journal: JNCI Journal of the National Cancer Institute (1976)

The proliferative behavior of neuroblastoma cells in bone marrow was evaluated before and after perturbation by chemotherapy. The data presented indicated that the proliferating fraction of the tumor cells before therapy was small. In most of the patients, initial therapy with a non-cell-cycle specific agent increased the mitotic and labeling indices. If initial therapy was followed by a cell cycle-specific agent, variable kinetic responses were observed. Although the number of patients was small and the follow-up was short, there was a correlation between the clinical response and the kinetic changes induced by the chemotherapy. Evaluation of cell kinetic changes during the initial course of chemotherapy might identify early those patients who are unlikely to have a good clinical response. Similar studies in the evaluation of new drugs to aid in identifying agents that favorably change cell kinetics and thus therapy for children with neuroblastoma was urged.
Intratracheal Instillation Studies With 7H-Dibenzo[c,g]carbazole in the Syrian Hamster2
Authors: Donald L. Nagel, Frej Stenbäck, David B. Clayson, Lawrence Wallcave
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Intratracheal Instillation Studies With 7H-Dibenzo[c,g]carbazole in the Syrian Hamster Get access Donald L. Nagel, Donald L. Nagel Search for other works by this author on: Oxford Academic PubMed Google Scholar Frej Stenbäck, Frej Stenbäck Search for other works by this author on: Oxford Academic PubMed Google Scholar David B. Clayson, David B. Clayson Search for other works by this author on: Oxford Academic PubMed Google Scholar Lawrence Wallcave Lawrence Wallcave Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 57, Issue 1, July 1976, Pages 119–123, https://doi.org/10.1093/jnci/57.1.119 Published: 01 July 1976 Article history Received: 15 September 1975 Accepted: 30 December 1975 Published: 01 July 1976
Validation of the Instant Blood Pressure Smartphone App
Authors: Timothy B. Plante, Bruno Urrea, Zane T. MacFarlane, Roger S. Blumenthal, Edgar R. Miller, Lawrence J. Appel, Seth S. Martin
Journal: JAMA Internal Medicine (2016)

The hope is that the focus on moving to more valuebased payment models will begin to bring in more measures of the effects this has on patient outcomes, which are the most important measure of the effects of changes in the use of health care services.That, along with the focus on comparative effectiveness analysis, which attempts to provide information on the differential clinical effects of using various interventions and treatment agents on different types of patients, should improve the ability to treat patients in a more clinically and cost-effective manner.To say that much remains in the path to accomplishing the objectives associated with value-based payment models is an understatement.However, this analysis suggests that the move to reduce overvalued payments can have differentiated effects, reducing the use of a procedure by physicians and other health care professionals who are not trained to use it while maintaining similar levels of its use by those who are trained in the use of the procedure.The CMS should consider using this strategy for other potentially overvalued services, particularly those that have a high cost, such as the use of proton beam therapy, which is a very expensive intervention with little clinical evidence supporting its use.
SAT0640-HPR Foot Problems in Patients with Systemic Lupus Erythematosus; Under-Recognised and Under-Treated?
Authors: S. Otter, S. Kumar, P. Gow, N. Dalbeth, M. Corkill, K.A. Davies, S. Panthakalam, K. Rome
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Foot pathology is common in inflammatory arthritis and the role of the podiatrist in the multidisciplinary care team is well established. However, in systemic lupus erythematosus; (SLE) the need for foot health services and service provision for foot disease is unknown. <h3>Objectives</h3> We set out to determine the perceived need and uptake of foot care services among people with SLE from the patients9 perspective. <h3>Methods</h3> We developed and tested a new 40-item item self-administered questionnaire, using a 5-stage development process we utilised patient involvement throughout to ensure face and content validity. This instrument was posted to 406 people with SLE attending adult rheumatology clinics across three health boards in Auckland New Zealand. The questionnaire enquired about the occurrence of foot symptoms and their frequency of assessment, the availability of podiatric services and the usefulness of interventions. <h3>Results</h3> From 131 responses, (89% women, mean (SD) age 51 (15.1), mean (SD) diagnosis 12.5 (11.1) years): 77% respondents experienced foot pain during the course of their lupus and almost one third (31%) reported difficulty with basic foot care. In total, 45% reported current foot pain and the mean (SD) score on a 10cm visual analogue scale was 4.9 (2.2). Half of the patients had discussed their foot pain with their general practitioner (50%) or rheumatologist (49%) and 35% reported ever having had a foot X-ray. Respondents reported there was no significant difference in the frequency with which their hands and feet were examined. Equally, there was no correlation between the reported severity of foot pain and the frequency of foot examination. Despite the frequency of foot complaints only 32.8% had been seen by a podiatrist. Insoles had been prescribed to less than a quarter of respondents (22%) but only 11% of those receiving foot insoles were continuing to wear them and merely three respondents (2%) indicated their foot symptoms had been resolved by their insoles. Being unable to replace insoles was the most commonly cited reason for not continuing with insole therapy. None of the subjects reported that they had been provided with specialist footwear and 8 subjects (6%) underwent foot surgery. <h3>Conclusions</h3> Foot problems appear to be under-recognised in patients with SLE. Health care professionals need to consider a comprehensive foot care plan as part of the holistic management of people with SLE. <h3>Acknowledgements</h3> We wish to thank the respondents who took the time to complete the questionnaire and our research assistants - Gemma Crawley, Hilary Otter and Heather Waddington. <h3>Disclosure of Interest</h3> None declared
The Gardner Syndrome: A Family Study in Cell Culture2
Authors: B. Shannon Danes, Anne J. Krush
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article The Gardner Syndrome: A Family Study in Cell Culture Get access B. Shannon Danes, B. Shannon Danes Search for other works by this author on: Oxford Academic PubMed Google Scholar Anne J. Krush Anne J. Krush Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 3, March 1977, Pages 771–775, https://doi.org/10.1093/jnci/58.3.771 Published: 01 March 1977 Article history Received: 20 April 1976 Accepted: 25 August 1976 Published: 01 March 1977
Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in patients with metastatic colorectal cancer: A sensitivity marker to 5-FU-based therapy
Authors: O. O. Castillo Fernandez, L. A. Herrera, C. Castro, G. Calderillo, R. Herrera, A. Bauza
Journal: Journal of Clinical Oncology (2007)

14532 Background: 5-Fluorouracil (5FU) and Folinic Acid (FA) with either oxaliplatin or irinotecan have become the standard chemotherapy used for metastatic colorectal cancer. However, more than 50% of our patients cannot afford it. Moreover, we lack of predictive markers to 5FU/AF therapy. The methylenetetrahydrofolate reductase (MTHFR) is a key enzyme regulating the folate pool and its substrate 5,10-methylenetetrahydrofolate is needed for modulation of 5FU. The C677T MTHFR gene polymorphism is highly prevalent in Mexican population and is linked to altered enzyme activity and increases substrate levels. Many studies have suggested a better response rate to fluoropyrimidine based therapy related with C677T polymorphism. The aim of this study was to evaluate the presence of this polymorphism and its relation with progression free and overall survival in metastatic colon cancer treated with 5FU/FA Methods: Sections of paraffin- embedded healthy colonic mucosa of 29 patients with metastatic unresectable colorectal cancer treated with 5FU/FA as first line chemotherapy between 1998 and 2004 were collected to obtain DNA and determine the polymorphism by PCR and allele specific digestion. Results: We found a highly proportion of at least one mutated allele in our patients (8 homozygous wild type CC, 15 heterozygous CT, 6 mutated homozygous TT). C677T MTHFR gene polymorphism showed statistically significant differences in median progression free survival non polymorphic CC 3.23±0.68 month versus 4.8±0.18 month in polymorphic group CT and TT (p= 0.011 log rank test) and median overall survival in non polymorphic groups 6.7±2.63month versus 13 ±2.51 month in polymorphic group (p= 0.03 Breslow test).No other variable affected progression free or overall survival on univariate analysis. Conclusions: Our findings suggest that C677T polymorphism could play a role on survival in metastatic colorectal cancer treated with 5FU/FA. Futher studies evaluating standard chemotherapy and the analyzed polymorphism are recommended. No significant financial relationships to disclose.
Triggering Noncycling Hematopoietic Progenitors and Leukemic Blasts to Proliferate Increases Anthracycline Retention and Toxicity by Downregulating Multidrug Resistance
Authors: Mariëlle E.P. Smeets, Reinier A.P. Raymakers, Gerty Vierwinden, Arie H.M. Pennings, Hans Wessels, Theo de Witte
Journal: Blood (1999)
Is the content and duration of the graduated return to play protocol after concussion demanding enough? A challenge for Berlin 2016
Authors: Simon Kemp, Jon Patricios, Martin Raftery
Journal: British Journal of Sports Medicine (2016)

Determining the appropriate starting point and duration of the return-to-play (RTP) process after injury is fundamental to clinical sports medicine. The most commonly cited RTP framework after concussion is outlined as part of all international concussion consensus statements. This framework is a key element of concussion management across all levels of sport and provides a ‘cornerstone’ of current education initiatives. In Rugby Union, RTP guidelines last underwent a major update by World Rugby, the International Federation, in 2011, and are consistent with international concussion consensus.

There is a limited evidence base informing the content and duration of the graduated return to play (GRTP). Specifically, the evidence evaluating the effect, optimal amount and type of rest is sparse. Moreover, current RTP guidelines for children and adolescents are based on those of adults.

While research concerning a range of clinical outcomes following concussive injury in sport continues to develop, until recently, little has been known about the consequences …
Treatment by in vitro fertilisation with surrogacy: experience of one British centre Surrogacy should pay
Authors: P. R Brinsden
Journal: BMJ (2000)

# Treatment by in vitro fertilisation with surrogacy: experience of one British centre {#article-title-2}

Surrogacy has been an accepted form of treatment for certain forms of childlessness for centuries.1 Until recently, “natural surrogacy” was the only means of helping certain women to have babies. In vitro fertilisation surrogacy is now accepted in the United Kingdom as a treatment option for infertile women with certain clearly defined medical problems (box).

#### Indications for treatment by in vitro fertilisation surrogacy

In 1985, despite opposition from the BMA, Mr Patrick Steptoe and Professor Robert Edwards, the pioneers of in vitro fertilisation, first proposed treating a patient by in vitro fertilisation surrogacy at Bourn Hall Clinic. After extensive discussions with the independent ethics committee they treated the first couple in the United Kingdom, and the child was born in 1989. In 1989, the clinic's ethics committee drew up guidelines for the treatment of women by in vitro fertilisation surrogacy, and the full programme was formalised in 1990 (table 1). Since then 49 “genetic couples” have received treatment. This review describes our experience of in vitro fertilisation surrogacy since 1989 and discusses some ethical and legal issues.

#### Summary points

Treatment by in vitro fertilisation surrogacy is accepted in the United Kingdom for appropriate indications

In depth counselling is essential for the preparation of couples for treatment

Treatment of the commissioning couple and the host is straightforward, but must be done in clinics licensed by the Human Fertilisation and Embryology Authority

Complications of treatment are minimal with appropriate selection and counselling of couples

Review of each surrogacy arrangement by an independent ethics committee is strongly recommended

In this review we have defined the couple who provide both sets of gametes as the genetic couple; they may also be known …
Electronic cigarettes: the renormalisation of nicotine use
Authors: Rehab Auf, Mary Jo Trepka, Miguel Angel Cano, Mario De La Rosa, Marah Selim, Elena Bastida
Journal: BMJ (2016)

We agree with McKee and Capewell’s article on Public Health England’s report.1 Unfortunately, the debate focuses on the potential harm reduction among dual users and diverts attention away from the harms of e-cigarettes,2 ignoring their impact on naive users, especially adolescents.

Despite the complete ban on …
P1145 : Activation and epithelial-to-mesenchymal transition of biliary tree stem cells within peribiliary glands are involved in the pathogenesis of primary sclerosing cholangitis
Authors: G. Carpino, V. Cardinale, A. Renzi, J.R. Hov, T.H. Karlsen, D. Alvaro, E. Gaudio
Journal: Journal of Hepatology (2015)
Parameters of prognostic relevance to the patency of vascular access in hemodialysis patients.
Authors: F C Prischl, A Kirchgatterer, E Brandstätter, M Wallner, C Baldinger, F X Roithinger, R Kramar
Journal: Journal of the American Society of Nephrology (1995)

The objectives of this study were to evaluate whether age, sex, underlying renal disease, or the performing surgeon is of prognostic relevance to the patency of the vascular access. In a routine clinical setting, 139 first and 144 further fistula operations were done in 139 patients during 5 yr and were analyzed in retrospect. Within a group of 108 patients with first Cimino-Brescia fistulae, Cox multivariate regression analysis revealed the surgeon to be the only determinant with a continuous, significant effect on fistula patency throughout the observation period (P(out) < 0.1). The patency rates of the seven surgeons at 1, 2, and 3 yr differed from 34 to 69, 13 to 62, and 13 to 62%, respectively. Hazard ratios among the surgeons varied from 0.65 to 2.21. Additionally, age (P < 0.004) and diabetes mellitus (P < 0.02) were disclosed to be significant risk factors for impaired patency, but later in the course of disease (time dependent). Sex had no influence. After the failure of the first fistula, revisions of or new Cimino-Brescia fistulae (N = 56) were superior to polytetrafluoroethylene grafts (N = 61). The mean patency of the former amounted to 320 +/- 377 versus 156 +/- 281 days in polytetrafluoroethylene grafts (P < 0.05). It was concluded that increasing age and diabetes mellitus are time-dependent risk factors for the shortened patency of arteriovenous fistulae. The operating surgeon, however, seems to be the major determinant for the continuous patency of Cimino-Brescia fistulae.
Killing of VRE<i>Enterococcus faecalis</i>by commensal strains: Evidence for evolution and accumulation of mobile elements in the absence of competition
Authors: Anthony O. Gaca, Michael S. Gilmore
Journal: Gut Microbes (2016)

Enterococci are members of the gastrointestinal tract of humans and most animals that, over the past 3 decades, have emerged as leading causes of multidrug resistant hospital acquired infection (HAI). In addition to their general hardiness, many traits have entered enterococcal lineages through horizontal gene transfer, which has led to the evolution of pathogenic hospital-associated lineages uniquely adapted for survival and proliferation in the antibiotic perturbed ecology of the gastrointestinal tract. We recently observed that the accretion of mobile genetic elements in the prototype vancomycin resistant E. faecalis, clinical isolate V583, renders it unable to co-exist with native enterococci in healthy human fecal flora. In this addendum, we discuss how these findings inform our understanding of how multidrug resistant enterococci evolve, and the implications for the development of treatments that limit colonization and spread of highly antibiotic refractory microbes of this type.
Polymers of Z α<sub>1</sub>-antitrypsin are secreted in cell models of disease
Authors: Annamaria Fra, Francesca Cosmi, Adriana Ordoñez, Romina Berardelli, Juan Perez, Noemi A. Guadagno, Luciano Corda, Stefan J. Marciniak, David A. Lomas, Elena Miranda
Journal: European Respiratory Journal (2016)

The α1-antitrypsin (α1-AT) is a 52 kDa glycoprotein that is predominantly synthesised in the liver and secreted into the circulation, where it protects the lungs from the enzyme neutrophil elastase. α1-AT deficiency (α1-ATD) is caused by mutations in the α1-AT gene, with most cases resulting from homozygous inheritance of the Z allele (Glu342Lys). This leads to low levels of circulating α1-AT, uncontrolled elastase activity and emphysema [1]. The Z mutation destabilises the native α1-AT and causes the formation of aberrant polymers that accumulate within the endoplasmic reticulum (ER) of hepatocytes, giving rise to inclusion bodies that are the main histological feature of α1-ATD [2]. Extracellular polymers have been found in lung lavage, the skin of an individual with panniculitis and the kidney of an individual with vasculitis [1], and are also present in the circulation of all individuals homo- or heterozygous for the Z allele [3]. Circulating polymers originate in the liver, since they became undetectable in the plasma of an individual 4 days after liver transplantation [3], but it is unknown whether polymers can be secreted from hepatocytes or can form in the extracellular environment from secreted monomeric Z α1-AT. Extracellular polymers are chemotactic and stimulatory for human neutrophils [4] and may contribute to inflammatory neutrophil infiltration in the lungs, kidney and skin. It is important to understand where these polymers form in order to design effective therapies for emphysema and other pathological manifestations of α1-ATD. Here we investigated the origin of extracellular polymers by exploiting our cellular models of α1-ATD and conformer-specific and functional monoclonal antibodies (mAb) against Z α1-AT [5–8]. Pathological polymers of Z alpha1-AT can be secreted from cells through the canonical secretory pathway <http://ow.ly/WHxZh> We thank Giulia Baldini (University of Arkansas for Medical Sciences, Little Rock, AR, USA) for providing tagged α1-antitrypsin vectors, Riccardo Ronzoni (University of Brescia, Brescia, Italy) for sharing reagents, Roberto Sitia (San Raffaele Scientific Institute, Milan, Italy), Bibek Gooptu (King's College London, London, UK) and James Irving (University College London, London, UK) for helpful discussions, and Nuccia Gatta (Associazione Nazionale Alpha1 AT Onlus, Brescia, Italy) and the Italian Alfa1 Patients' Association for constant encouragement.
Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection
Authors: Mei Lu, Jia Li, Talan Zhang, Loralee B. Rupp, Sheri Trudeau, Scott D. Holmberg, Anne C. Moorman, Philip R. Spradling, Eyasu H. Teshale, Fujie Xu, Joseph A. Boscarino, Mark A. Schmidt, Vinutha Vijayadeva, Stuart C. Gordon, Scott D. Holmberg, Eyasu H. Teshale, Philip R. Spradling, Anne C. Moorman, Fujie Xu, Jim Xing, Cindy Tong, Stuart C. Gordon, David R. Nerenz, Mei Lu, Lois Lamerato, Jia Li, Loralee B. Rupp, Nonna Akkerman, Nancy Oja-Tebbe, Talan Zhang, Joseph A. Boscarino, Zahra S. Daar, Robert E. Smith, Vinutha Vijayadeva, John V. Parker, Mark A. Schmidt, Judy L. Donald, Erin M. Keast
Journal: Clinical Gastroenterology and Hepatology (2016)